BACKGROUND: There are elevated rates of comorbid psychiatric disorders among individuals with substance dependence; however, little research examines these rates within inpatient settings, particularly in relation to gender and type of substance. The current study aimed to fill this gap. METHOD: 465 patients (71.4% male) were recruited from an inpatient substance use treatment facility from 2006 to 2009. These patients were interviewed and diagnosed using the Structure Clinical Interview for DSM-IV and the Diagnostic Interview for Personality Disorders. RESULTS: 60.6% of patients with substance dependence had a current comorbid psychiatric disorder, and more than 30% had at least two psychiatric disorders. The most common current Axis I diagnosis was major depressive disorder (25.8%), followed by PTSD (14%). Comparable rates were found for Antisocial and Borderline Personality Disorders. Females were significantly more likely to meet diagnostic criteria for a psychiatric disorder than were males (73.7% versus 55.4%). When examining comorbidities across different substance dependences, the highest rates of comorbid psychiatric disorders were found among individuals with alcohol dependence (76.8%) and cannabis dependence (76%), although rates were above 60% for cocaine and opioid dependence. Rates of psychiatric diagnoses were significantly lower (27%) among patients who did not meet diagnostic criteria for substance dependence. CONCLUSIONS: There are particularly elevated rates of psychiatric disorders among individuals with substance dependence in inpatient treatment. These rates differ as a function of substance dependence type and gender, making these factors important to consider when researching and treating this type of population.
BACKGROUND: There are elevated rates of comorbid psychiatric disorders among individuals with substance dependence; however, little research examines these rates within inpatient settings, particularly in relation to gender and type of substance. The current study aimed to fill this gap. METHOD: 465 patients (71.4% male) were recruited from an inpatient substance use treatment facility from 2006 to 2009. These patients were interviewed and diagnosed using the Structure Clinical Interview for DSM-IV and the Diagnostic Interview for Personality Disorders. RESULTS: 60.6% of patients with substance dependence had a current comorbid psychiatric disorder, and more than 30% had at least two psychiatric disorders. The most common current Axis I diagnosis was major depressive disorder (25.8%), followed by PTSD (14%). Comparable rates were found for Antisocial and Borderline Personality Disorders. Females were significantly more likely to meet diagnostic criteria for a psychiatric disorder than were males (73.7% versus 55.4%). When examining comorbidities across different substance dependences, the highest rates of comorbid psychiatric disorders were found among individuals with alcohol dependence (76.8%) and cannabis dependence (76%), although rates were above 60% for cocaine and opioid dependence. Rates of psychiatric diagnoses were significantly lower (27%) among patients who did not meet diagnostic criteria for substance dependence. CONCLUSIONS: There are particularly elevated rates of psychiatric disorders among individuals with substance dependence in inpatient treatment. These rates differ as a function of substance dependence type and gender, making these factors important to consider when researching and treating this type of population.
Authors: R A Brown; P M Monti; M G Myers; R A Martin; T Rivinus; M E Dubreuil; D J Rohsenow Journal: Am J Psychiatry Date: 1998-02 Impact factor: 18.112
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Michael J McDermott; Joshua C Fulwiler; Todd A Smitherman; Kim L Gratz; Kevin M Connolly; Matthew T Tull Journal: J Behav Med Date: 2015-11-26
Authors: S B Taylor; L R Watterson; P R Kufahl; N E Nemirovsky; S E Tomek; C D Conrad; M F Olive Journal: Neuropharmacology Date: 2016-05-07 Impact factor: 5.250
Authors: Anne N Banducci; Jennifer Dahne; Jessica F Magidson; Kevin Chen; Stacey B Daughters; C W Lejuez Journal: Addict Behav Date: 2012-12-24 Impact factor: 3.913
Authors: Natalia Albein-Urios; José Miguel Martínez-González; Oscar Lozano; Antonio Verdejo-Garcia Journal: Psychopharmacology (Berl) Date: 2013-03-13 Impact factor: 4.530